Our portfolio

Jeito Capital is building a strong and diversified portfolio in Biopharma and innovative medical companies.

Neogene Therapeutics

Oncology - Cell Therapy
Acquired by AstraZeneca, finalised in January 2023 – Round of $110 million in September 2020

Sparing Vision

Ophtalmology - Gene Therapy
Rounds of €44,5 million in September 2020 – €75 million in Septembre 2022

Pulmocide

Inhaled Respiratory Medicine
Rounds of $92 million in May 2021 – $52 million in December 2022

Alentis Therapeutics

Cancers and Organ fibrosis
Rounds of €55 million in June 2021 – €96 million in April 2023 – €164.5 million in November 2024

Quell Therapeutics

T-reg cell therapy in auto-immune and inflammatory diseases
Round of $156 million in November 2021

Advesya

IMMUNO-ONCOLOGY THERAPIES
Round of €23 million in February 2022

NMD Pharma

Severe neuromuscular diseases
Rounds of €35 million in February 2022 – €75 million in November 2023

EyeBio

Eye disease therapies
Acquired by Merck & Co, finalised in July 2024 – Rounds of $65 million in February 2022 – $65 million in November 2023

Precirix

Oncology therapies
Round of €80 million in March 2022

CDR-Life

Immuno-oncology therapies
Round of $76 million in April 2022

HI-Bio

Auto-Immune Diseases - Antibody
Acquired by Biogen Inc., finalised in July 2024 – Rounds of $120 million in November 2022 – $95 million in January 2024

CatalYm

Immuno-Oncology Therapies
Rounds of €50 million in November 2022 – $150 million in July 2024

Noema Pharma

DEBILITATING CENTRAL NERVOUS SYSTEM DISORDERS
Round of €104 million in March 2023

Corteria Pharmaceuticals

CARDIOVASCULAR DISEASES
Round of €65 million in September 2023

At a glance

key data

investments in portfolio

millions euros under management

In short

Discover Jeito news

Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.